Tutti gli studi
Attivo ma non reclutanteFASE3INTERVENTISTICO

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

This study is investigating a new tablet called Venglustat for people aged 16 and older who have Fabry disease. The main goal is to see if Venglustat can ease nerve pain in the arms and legs, and tummy pain, compared to a placebo (a dummy tablet with no medicine). We are looking for people who haven't been treated for Fabry disease for at least six months, or who have never been treated before. Participants will take either Venglustat or the placebo for 12 months. After this, everyone will have the chance to take Venglustat in an open-label extension part of the study. Regular check-ups will happen about every three months to see how you are doing.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE3
Sponsor
Sanofi
Obiettivo di iscrizione
122
Inizio
11 Mar 2022
Completamento stimato
04 Jan 2027

Di cosa tratta questo studio?

This study is focusing on Fabry disease, a rare genetic condition that can cause various health problems, including significant pain. Specifically, we are looking at nerve pain in the arms and legs (neuropathic pain) and tummy pain (abdominal pain).

We are testing a new medicine called Venglustat, which comes in tablet form. The main purpose of this research is to find out if Venglustat can help reduce these painful symptoms in people with Fabry disease. We compare it to a 'placebo', which looks exactly like the study medicine but doesn't contain any active drug. This helps us understand if the new medicine is truly effective.

This is a 'Phase 3' study, which means it's one of the final steps before a new medicine might become widely available. Doctors and scientists are hopeful that Venglustat could offer a new way to manage these challenging pain symptoms for people living with Fabry disease.

Punti chiave

  • Tests a new tablet (Venglustat) for Fabry disease pain.
  • Compares Venglustat to a dummy tablet (placebo) first.
  • Open to people aged 16+ who haven't recently been treated for Fabry.
  • Involves regular check-ups (every 3 months) for up to 4 years.
  • Puoi smettere di partecipare in qualsiasi momento.
  • Your health will be closely monitored throughout.

Chi può essere idoneo?

You might be able to join this study if you are 16 years old or older and have a confirmed diagnosis of Fabry disease with symptoms. We are looking for people who haven't received treatment for Fabry disease in the last six months, or who have never been treated for it before. A key part of joining is having an average pain score of 3 or more (on a scale of 0 to 10, where 10 is the worst pain imaginable) for either nerve pain in your arms or legs, or tummy pain.

However, there are reasons why you might not be able to take part. For example, if you have certain other serious health conditions like a recent heart attack, stroke, or uncontrolled high blood pressure. You also wouldn't be able to join if you have certain infections like Hepatitis C, HIV, or Hepatitis B, or if your pain is known to be caused by something other than Fabry disease.

If you're thinking about joining, it's important that you or your partner (if you are a man) are using effective birth control methods, and women should not be pregnant or breastfeeding. We also need to check your kidney function and other health markers to make sure it's safe for you to take part.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 16 anni o più?
  2. Do you have a diagnosis of Fabry disease with symptoms?
  3. Have you not received Fabry disease treatment for at least the past 6 months (or ever)?
  4. Do you experience nerve pain in your arms/legs or tummy pain, scoring 3 or more out of 10?
  5. Are you able to use effective birth control if required?
  6. Do you generally have good health apart from your Fabry disease?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to join, the study will have two main parts. For the first 12 months, you will take either the study medicine (Venglustat) or a dummy tablet (placebo). Neither you nor your study doctor will know which one you are taking – this is called 'double-blind'. During this time, you'll have study visits about every three months to check on your health and how you're feeling.

After these 12 months, if you wish to continue and have completed the first part, you will enter an 'open-label' period. This means everyone will receive Venglustat, and both you and your doctor will know you're taking the active medicine. This part could last for another 12 months, or potentially longer, until all participants finish the study at the same time. The total time you could be in the study, including initial checks and follow-up, could be up to about 46 months (nearly 4 years). Throughout, there will be regular checks to make sure you are safe and that the medicine is well tolerated.

Rischi e benefici potenziali

Taking part in this study could offer you potential benefits, such as receiving a new investigational medicine that might improve your Fabry disease symptoms. You will also get close medical monitoring and care during the study. However, like all medicines, Venglustat may have side effects, and some people may experience no improvement or even worsening of symptoms. You might also receive the placebo during the first 12 months, meaning you wouldn’t be getting active treatment. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (50)

  • University of Alabama -The Kirklin Clinic- Site Number : 8400011
    Codice postale verificato
    Birmingham, Stati Uniti
  • David Geffen School of Medicine at UCLA- Site Number : 8400006
    Codice postale verificato
    Los Angeles, Stati Uniti
  • University of California Irvine Medical Center- Site Number : 8400019
    Codice postale verificato
    Orange, Stati Uniti
  • AdventHealth Orlando- Site Number : 8400008
    Codice postale verificato
    Orlando, Stati Uniti
  • Emory University School of Medicine - Atlanta- Site Number : 8400010
    Codice postale verificato
    Atlanta, Stati Uniti
  • WMCHealth Advanced Physician Services- Site Number : 8400001
    Codice postale verificato
    Hawthorne, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400013
    Codice postale verificato
    Cincinnati, Stati Uniti
  • UPMC Montefiore- Site Number : 8400009
    Codice postale verificato
    Pittsburgh, United States
  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012
    Codice postale verificato
    Dallas, Stati Uniti
  • University of Utah Health Hospital- Site Number : 8400005
    Codice postale verificato
    Salt Lake City, United States
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
    Codice postale verificato
    Fairfax, United States
  • Investigational Site Number : 0320001
    Codice postale verificato
    Pergamino, Argentina

Domande comuni

What is Fabry disease?

Fabry disease is a rare genetic condition that can affect many parts of the body, including the nerves, kidneys, and heart, often causing pain and other symptoms.

Cosa significa 'placebo'?

A placebo is a dummy tablet that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the new medicine's effects.

Per quanto tempo sarò nello studio?

The first main part of the study is 12 months. If you continue, the study could last up to about 46 months (nearly 4 years) in total.

Will I know if I'm getting the active medicine?

For the first 12 months, neither you nor your doctor will know if you're taking Venglustat or the placebo. After that, if you continue, you will know you are taking Venglustat.

What kind of pain is the study looking at?

This study is focused on nerve pain in the arms and legs, and tummy pain, that is related to your Fabry disease.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.